Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574491 | 0.86 | MEN1 (0.40) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18031763 | 0.86 | MEN1 (0.40) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21294295 | 0.86 | MEN1 (0.40) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21294262 | 0.86 | THRB (0.46) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26835589 | 0.84 | MAPT (0.47) | PTGS1MAPTNPC1RAB9ATHRB | |
| SCHEMBL18031756 | 0.82 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL18031760 | 0.81 | ESR1 (0.44) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17995511 | 0.80 | PTGS1 (0.47) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18033878 | 0.79 | MAPT (0.47) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21294303 | 0.79 | MAPT (0.40) | PTGS1MAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117304157-A | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-112189009-B | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3059231-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | Artax Biopharma Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2623503-B1 | CHROMENE DERIVATIVES USEFUL IN THE TREATMENT OF A DISEASE MEDIATED BY THE TCR-NCK INTERACTION | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-09-23 | — | — | EP | disclosed |
| EP-2623503-B1 | CHROMENE DERIVATIVES USEFUL IN THE TREATMENT OF A DISEASE MEDIATED BY THE TCR-NCK INTERACTION | CONSEJO SUPERIOR INVESTIGACION (ES) | 2015-09-23 | — | — | EP | disclosed |
| US-9120764-B2 | Chromene derivatives | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-09-01 | — | — | US | disclosed |
| US-9120764-B2 | Chromene derivatives | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-09-01 | — | — | US | disclosed |
| US-20140005247-A1 | CHROMENE DERIVATIVES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2014-01-02 | — | — | US | disclosed |
| EP-2623503-A1 | CHROMENE DERIVATIVES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623503-A1 | CHROMENE DERIVATIVES | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012042078-A1 | CHROMENE DERIVATIVES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
| US-20140005247-A1 | CHROMENE DERIVATIVES | CD4, NCK1, NCKAP1 | PTGS1 4277/4885MAPT 3254/4885NPC1 1998/4885 |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | NFATC1, NCKAP1, NCK1 | PTGS1 2989/4885MAPT 3281/4885NPC1 2020/4885 |
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | PTGS1 4468/4885MAPT 2456/4885NPC1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.